Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management Guidelines

abstract

Cardio-facio-cutaneous syndrome (CFC) is one of the RASopathies that bears many clinical features in common with the other syndromes in this group, most notably Noonan syndrome and Costello syndrome. CFC is genetically heterogeneous and caused by gene mutations in the Ras/mitogen-activated protein kinase pathway. The major features of CFC include characteristic craniofacial dysmorphology, congenital heart disease, dermatologic abnormalities, growth retardation, and intellectual disability. It is essential that this condition be differentiated from other RASopathies, as a correct diagnosis is important for appropriate medical management and determining recurrence risk. Children and adults with CFC require multidisciplinary care from specialists, and the need for comprehensive management has been apparent to families and health care professionals caring for affected individuals. To address this need, CFC International, a nonprofit family support organization that provides a forum for information, support, and facilitation of research in basic medical and social issues affecting individuals with CFC, organized a consensus conference. Experts in multiple medical specialties provided clinical management guidelines for pediatricians and other care providers. These guidelines will assist in an accurate diagnosis of individuals with CFC, provide best practice recommendations, and facilitate long-term medical care. Pediatrics 2014;134:e1149–e1162

AUTHORS: Mary Ella M. Pierpont, MD, PhD,a,b Pilar L. Magoulas, MS,c Saleh Adi, MD,d Maria Ines Kavamura, MD, PhD,e Giovanni Neri, MD,f Jacqueline Noonan, MD,g Elizabeth I. Pierpont, PhD,h Kent Reinker, MD,i Amy E. Roberts, MD,j Suma Shankar, MD, PhD,k Joseph Sullivan, MD,l Melinda Wolford, PhD,m Brenda Conger, MS,n Molly Santa Cruz, BS,o and Katherine A. Rauen, MD, PhDp

aDivision of Genetics and Metabolism, Department of Pediatrics and Ophthalmology, and bDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; cChildren’s Hospitals and Clinics of Minnesota, Saint Paul, Minnesota; dDepartment of Molecular and Human Genetics, Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas; eMadison Clinic for Pediatric Diabetes, Benioff Children’s Hospital and University of California at San Francisco, San Francisco, California; fMedical Genetics Center, Federal University of Sao Paulo, Sao Paulo, Brazil; gInstitute of Medical Genetics, A Gemelli School of Medicine, Catholic University, Rome, Italy; hDepartment of Pediatrics, University of Kentucky, Lexington, Kentucky; iDepartment of Orthopedics, University of Texas Health Sciences Center, San Antonio, Texas; iDepartment of Cardiology and Division of Genetics, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts; jDepartments of Human Genetics and Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; kDepartments of Neurology and Pediatrics, University of California at San Francisco, San Francisco, California; lDepartment of Counseling, Special Education and School Psychology, Youngstown State University, Youngstown, Ohio; mCFC International, Vestal, New York; nDivision of Genomic Medicine, Department of Pediatrics, UC Davis MIND Institute, University of California at Davis, Sacramento, California

KEY WORDS

cardio-facio-cutaneous syndrome, BRAF mutation, management guidelines, MEK1 mutation, MEK2 mutation, RASopathy

ABBREVIATIONS

CFC—cardio-facio-cutaneous syndrome
CS—Costello syndrome
GH—growth hormone
HCM—hypertrophic cardiomyopathy
IGF—insulinlike growth factor
MAPK—mitogen-activated protein kinase
NS—Noonan syndrome
PVS—pulmonary valvular stenosis

(Continued on last page)
Cardio-facio-cutaneous syndrome (CFC) is a multiple congenital anomaly disorder that belongs to a group of syndromes known as RASopathies. Although CFC has distinctive characteristics, many of the clinical features overlap with 2 other RASopathies, namely Noonan syndrome (NS) and Costello syndrome (CS), therefore making the diagnosis challenging, especially in the newborn period. CFC is an autosomal dominant disorder with the vast majority of cases arising by a new mutation of BRAF, MEK1, MEK2 or rarely, KRAS genes. The most common findings include dysmorphic craniofacial features, congenital heart disease, dermatologic abnormalities, failure to thrive, gastrointestinal dysfunction, neurocognitive delay, and seizures.

It is often challenging to differentiate CFC from other RASopathies; therefore, CFC International convened an international conference on November 5–6, 2012, composed of health care providers and physician-scientists with expertise in CFC to aid in establishing a correct diagnosis and provide optimum clinical management to patients. The goal of this conference was to review the most current medical and scientific information about CFC, and develop guidelines for its diagnosis and clinical management. With this, we set forth timely recommendations for best practices and comprehensive medical management for individuals with CFC (Table 1).

### HISTORY

CFC was first reported in 1986 by Reynolds et al and by Baraitser and Patton. Eight individuals were described with distinct facial features, ectodermal abnormalities, cardiac malformations, and intellectual disability. At that time, many believed that the facial features of CFC were similar to those of Noonan syndrome and Costello syndrome, which has since been clarified.

### MANAGEMENT RECOMMENDATIONS FOR CFC

<table>
<thead>
<tr>
<th>Clinical Specialty</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics</td>
<td>At risk for CFC based upon physical examination, developmental history, and medical history.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Genetics consultation.</td>
</tr>
<tr>
<td></td>
<td>• Genetic testing directed by a geneticist/genetics provider using multigene Ras/MAPK pathway panel testing (if available). Approximately 80% mutation detection rate for CFC.</td>
</tr>
<tr>
<td></td>
<td>• Consider sequential gene testing if panel testing is not available: (1) BRAF (2) MEK1 and MEK2, and (3) KRAS.</td>
</tr>
<tr>
<td></td>
<td>• Parental testing if variant of uncertain significance is detected.</td>
</tr>
<tr>
<td></td>
<td>• Consider high-resolution chromosome microarray if gene testing is negative.</td>
</tr>
<tr>
<td></td>
<td>• If the above testing is negative, the geneticist/genetics provider can determine if exome sequencing is appropriate.</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Annual follow-up with geneticist/genetics provider or specialty Ras pathway clinic.</td>
</tr>
<tr>
<td>Dermatologic</td>
<td>At risk for keratitis pilaris, ulerythema ophryogenes, eczema, progressive multiple pigmented nevi, dystrophic nails, lymphedema, hemangiomas, hyperkeratosis, and generalized hyperpigmentation.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Consultation with a dermatologist.</td>
</tr>
<tr>
<td></td>
<td>• Evaluation of hemangiomas.</td>
</tr>
<tr>
<td></td>
<td>• Evaluation of pigmented nevi.</td>
</tr>
<tr>
<td></td>
<td>• If lymphedema present, referral to vascular specialist/clinic.</td>
</tr>
<tr>
<td></td>
<td>Ongoing management:</td>
</tr>
<tr>
<td></td>
<td>• Frequent dermatology visits for management of xerosis, hyperkeratosis, and eczema.</td>
</tr>
<tr>
<td></td>
<td>• Annual evaluation of pigmented nevi.</td>
</tr>
<tr>
<td></td>
<td>• Referral to a podiatrist for dystrophic nails or hyperkeratosis if needed.</td>
</tr>
<tr>
<td></td>
<td>• Monitor for lymphedema.</td>
</tr>
<tr>
<td></td>
<td>• Meticulous skin care and early treatment of skin infection in the context of lymphedema.</td>
</tr>
<tr>
<td></td>
<td>• Sun protection as recommended for the general population (ie, sunscreen; hats).</td>
</tr>
<tr>
<td>Neurologic</td>
<td>At risk for infantile spasms, seizures, hydrocephalus, type I Chiari malformation, and other structural brain anomalies.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Referral to neurologist for a baseline evaluation.</td>
</tr>
<tr>
<td></td>
<td>• Families should receive anticipatory guidance about the risk of seizures (infantile spasms, other seizure types) and other neurologic issues.</td>
</tr>
<tr>
<td></td>
<td>• Brain MRI should be obtained in cases of rapid increase in head growth, infantile spasms, changes in neurologic examination, and regression of skills.</td>
</tr>
<tr>
<td></td>
<td>• EEG if there is a suspicion of seizure activity.</td>
</tr>
<tr>
<td></td>
<td>• Accurate seizure classification with clinical history and EEG to help guide medical management.</td>
</tr>
<tr>
<td></td>
<td>Ongoing management:</td>
</tr>
<tr>
<td></td>
<td>• Continued follow-up with neurologist for seizure management (if present).</td>
</tr>
<tr>
<td></td>
<td>• In child with infantile spasms, consult with cardiologist for possible steroid management due to risk of cardiomyopathy.</td>
</tr>
<tr>
<td></td>
<td>• If peripheral neuropathy suspected, consult with neurologist for nerve conduction velocities and electromyogram.</td>
</tr>
</tbody>
</table>
TABLE 1 Continued

<table>
<thead>
<tr>
<th>Clinical Specialty</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive and behavioral</td>
<td>At risk for intellectual disability, delayed fine and gross motor skills, emotional and behavioral problems, atypical sensory processing, and speech/language impairments.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Referral to early childhood services or local school system for needs assessment and intervention.</td>
</tr>
<tr>
<td></td>
<td>• Speech and language evaluation including assessment of oral-motor functioning, articulation, and expressive/receptive language ability. Speech and language therapy as indicated based on evaluation. For severe delays, consideration of alternative or augmentative communication systems.</td>
</tr>
<tr>
<td></td>
<td>• Physical therapy (specific attention to hypotonia and gross motor delay).</td>
</tr>
<tr>
<td></td>
<td>• Occupational therapy (specific attention to hypotonia, sensory integration, and vision concerns).</td>
</tr>
<tr>
<td></td>
<td>• Behavioral therapy, mental health services, and/or alternative therapies may be considered to address behavioral, sensory, motor, social, emotional, and/or communication concerns.</td>
</tr>
<tr>
<td></td>
<td>Ongoing management:</td>
</tr>
<tr>
<td></td>
<td>• Continued evaluation and services by early childhood intervention programs in early childhood.</td>
</tr>
<tr>
<td></td>
<td>• Upon school entry, physician referral for a full neuropsychological evaluation.</td>
</tr>
<tr>
<td></td>
<td>• Upon school entry, school professionals and families should collaboratively develop an Individualized Education Plan (IEP) and/or other accommodation plan. Clarity should be established regarding medical diagnosis and eligibility for special education services.</td>
</tr>
<tr>
<td></td>
<td>• If behavioral concerns exist, a functional behavior assessment may be indicated to assist in development of a behavior intervention plan (specific attention to sensory concerns, communication skills, and attentional ability).</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>At risk for feeding and/or swallowing difficulties, FTT, constipation, gastroesophageal reflux, and intestinal malrotation.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Nutrition assessment/growth measurements by primary physician.</td>
</tr>
<tr>
<td></td>
<td>• Refer to gastroenterologist in early infancy for feeding difficulties, gastroesophageal reflux, and poor growth.</td>
</tr>
<tr>
<td></td>
<td>• If feeding difficulties are present, referral for feeding therapy evaluation and recommendations.</td>
</tr>
<tr>
<td></td>
<td>• Evaluate for gastroesophageal reflux and swallowing dysfunction by swallowing studies, pH studies, upper gastrointestinal series, and endoscopy studies as recommended by gastroenterologist.</td>
</tr>
<tr>
<td></td>
<td>• Consider treatment with proton pump inhibitors for gastroesophageal reflux.</td>
</tr>
<tr>
<td></td>
<td>• Consider assisted feeding for FTT (nasogastric or gastrostomy tube), found to be necessary in 40% to 50% with CFC. Surgical recommendations to be assisted by gastroenterologist.</td>
</tr>
<tr>
<td></td>
<td>• If feeding difficulties are present, then refer for feeding therapy evaluation.</td>
</tr>
<tr>
<td></td>
<td>Ongoing management:</td>
</tr>
<tr>
<td></td>
<td>• Regular follow-up to monitor growth and nutrition.</td>
</tr>
<tr>
<td></td>
<td>• Continued feeding therapy if there are persistent feeding difficulties.</td>
</tr>
<tr>
<td></td>
<td>• Treatment of gastroesophageal reflux and constipation as needed as children get older.</td>
</tr>
<tr>
<td>Growth/ Endocrine</td>
<td>At risk for failure to thrive, short stature, GH deficiency, GH resistance, and delayed puberty.</td>
</tr>
<tr>
<td></td>
<td>At diagnosis:</td>
</tr>
<tr>
<td></td>
<td>• Refer to endocrinologist between ages 2 and 3 y for growth monitoring or earlier if there are concerns about growth.</td>
</tr>
<tr>
<td></td>
<td>• Obtain thyrotropin, free thyroxine, IGF-1, and IGF-BP3 levels because thyroid and GH abnormalities are seen in other RASopathies.</td>
</tr>
<tr>
<td></td>
<td>• Nutritional assessment/growth measurements by primary physician.</td>
</tr>
<tr>
<td></td>
<td>Ongoing management:</td>
</tr>
<tr>
<td></td>
<td>• Monitor growth carefully (height, weight, and head circumference at each visit) and refer to appropriate specialists if significant change in growth curves (eg, endocrinologist, gastroenterologist, neurologist, or neurosurgeon).</td>
</tr>
<tr>
<td></td>
<td>• Regular follow-up by endocrinologist if growth failure, GH deficiency, or thyroid hormone abnormality.</td>
</tr>
<tr>
<td></td>
<td>• If growth failure: thyroid function studies, celiac disease screening, GH stimulation studies to be directed by endocrinologist.</td>
</tr>
<tr>
<td></td>
<td>• Monitor pubertal development beginning around age 10 y.</td>
</tr>
</tbody>
</table>

In 2001, PTPN11 was found to be one of the causal genes of NS, and it was possible to demonstrate that well-characterized individuals with CFC did not have a mutation in PTPN11. Furthermore, individuals with CFC did not carry mutations in the HRAS gene, which causes CS, another phenotypically similar condition. Identification of these 2 genes for NS and CS suggested that CFC, NS, and CS were separate, distinct conditions, with overlapping phenotypes.

The final proof came in 2006 when 2 groups demonstrated that CFC is a heterogeneous disorder caused by mutations in 4 different genes: BRAF, MEK1, MEK2, and KRAS. These discoveries led to the recognition that CFC was a distinct syndrome separate from NS and CS and also explained that the similarity between them lay in a common underlying molecular pathway, the Ras/mitogen-activated protein kinase (MAPK) pathway.

Molecular Characterization

The Ras/MAPK pathway is one of the most studied signaling cascades and is well known for its role in oncogenesis and tumor progression. This pathway is critically involved in cell proliferation, differentiation, motility, apoptosis, and senescence. CFC is caused by dysregulation of the Ras/MAPK pathway due to heterozygous activating mutations in protein kinases, BRAF, MEK1, MEK2, or KRAS. Mutations in KRAS, a small GTPase, have been implicated as causing both CFC and NS.

Heterozygous BRAF mutations are found in ~75% of mutation-positive CFC individuals. BRAF, an onco-protein, is a serine/threonine protein kinase and one of downstream effectors of Ras. Most BRAF mutations are missense and found in exons 6 and 12 and confer an activation of
TABLE 1 Continued

<table>
<thead>
<tr>
<th>Clinical Specialty/audiology</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At diagnosis:</strong></td>
<td></td>
</tr>
<tr>
<td>1. Referral to otolaryngologist for airway evaluation/management in the case of neonatal or early respiratory issues.</td>
<td></td>
</tr>
<tr>
<td>2. Referral to otolaryngologist for hearing loss management.</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management:</strong></td>
<td></td>
</tr>
<tr>
<td>1. Audiologic assessment every 2-3 y or more frequently if necessary. Hearing aids as needed.</td>
<td></td>
</tr>
<tr>
<td>2. Otolaryngology follow-up for management of airway.</td>
<td></td>
</tr>
</tbody>
</table>

**At diagnosis:**
- Referral to a pediatric ophthalmologist.
- Early intervention as appropriate (ie, correction of ptosis, prescription glasses for refractive errors or strabismus, patching for amblyopia).

**Ongoing management:**
- Follow-up every 6-12 mo or more frequently as recommended by ophthalmologist.
- Visual functional assessment by early childhood programs and vision resources for poor vision and abnormal depth perception.
- In those with optic nerve abnormalities, MRI of brain should be obtained to screen for malformations that could cause optic atrophy.

**Renal/genitourinary**

At diagnosis:
- Renal ultrasound to evaluate for structural renal anomalies.
- Refer to urologist and endocrinologist if cryptorchidism present.

**Ongoing management:**
- As indicated by urologist.

**Hematology/oncology**

At risk for easy bruising, von Willebrand disease, and thrombocytopenia.

At diagnosis:
- Obtain history regarding easy bruising or bleeding problems.
- If easy bruising or bleeding problems are present, screen with CBC, platelet count, platelet function study, and von Willebrand screen.
- Refer to a hematologist for an abnormal CBC.

**Ongoing management:**
- If evidence of easy bruising or bleeding appears with time, then screen with CBC, platelet count, platelet function study, and von Willebrand screen.
- If patient requires surgery, screen with the above testing before surgery if not already done.
- For those on divalproex sodium for seizures, obtain platelet count every 6 mo.

**Dental**

At risk for malocclusion, posterior crossbite, and bruxism.

At diagnosis:
- Dental evaluation.

---

CFC is typically the result of a de novo heterozygous mutation. It is very rare for individuals with CFC to reproduce. Germline mosaicism has yet to be reported.

**GENOTYPE/PHENOTYPE CORRELATIONS**

Few genotype–phenotype studies of CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.

CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.

CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.

CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.

CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.

CFC have been performed to date. One statistically significant genotype–phenotype correlation is the incidence of pulmonic stenosis, which is present in 50% of individuals with CFC with a BRAF gene mutation and 37% of those with a MEK gene mutation. It also appears that, while not statistically significant, MEK mutations may be associated with a higher likelihood of prematurity, ventricular septal defects, pectus deformity, urogenital abnormalities, and dermatological abnormalities, whereas BRAF mutations may be more commonly associated with hypertrophic cardiomyopathy (HCM), atrial septal defects, moderate to severe intellectual disability, and significant feeding difficulties.

Among the RASopathies as a whole, there are relatively well-established genotype–phenotype correlations with respect to cognitive development. Mutations associated with CFC and CS tend to correspond to greater impairments in intellectual and adaptive functioning than mutations in the oncprotein. The most common BRAF mutations occur in exon 6 (p.Q257R), in exon 12 at p.E501, and in exon 11 (p.G469E). Heterozygous mutations in MEK1 (MAP2K1) and MEK2 (MAP2K2) are present in ~25% of CFC individuals in which a gene mutation has been identified. The most common missense MEK mutation is MEK1 p.Y130C. MEK1 and MEK2 are threonine/tyrosine kinases, with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. Functional studies of MEK mutant CFC proteins have shown that all are activating.
associated with NS.17–19 Although some reports indicate that individuals with MEK mutations have milder intellectual disabilities when compared with those with BRAF mutations, the numbers are still too small to reach statistical significance.15,20 There is some preliminary evidence to suggest that the most common BRAF missense mutation, p.Q257R, may be associated with fewer developmental delays than other BRAF mutations.19 Further studies are required to determine if this will be confirmed.

KRAS mutations can be found in individuals with the clinical diagnosis of both CFC and NS.16,21,22 In general, individuals with a KRAS mutation have mild to moderate intellectual disability, dysmorphic facial features, short stature, dermatologic abnormalities, and ophthalmologic abnormalities. Regardless of phenotypic assignment, it is essential to establish the molecular etiology of all individuals with CFC to provide appropriate medical care. Additionally, the molecular confirmation will be important for genetic counseling and understanding of recurrence risk and natural history.

**GENETIC TESTING FOR CFC SYNDROME**

All individuals suspected to have CFC should undergo examination and molecular testing directed by a geneticist who can determine the most appropriate and cost effective type of testing and can provide explanations of the results obtained to the family and other health providers. Current commercial tests for the molecular diagnosis of CFC include the following: (1) next-generation sequencing of multigene panels of the common RASopathy genes, (2) individual single gene sequencing, and (3) chromosome microarray to screen for copy number abnormalities. Multigene panel testing is usually the preferred initial test and will detect a mutation in ∼70% to 90% of individuals with the clinical diagnosis of CFC.15 If panel testing is not available, sequential gene testing is recommended, beginning with BRAF, MEK1 and MEK2, and KRAS. In the event that a variant of uncertain significance is identified, parental testing and physical examination is recommended to determine if the variant was inherited. If molecular testing of the CFC genes is negative, the geneticist can arrange for testing of the other Rasopathy genes if they have not yet been done and consider other conditions in the differential diagnosis (Table 2). If these are negative, the geneticist may consider a chromosome microarray analysis to screen for microdeletions/microduplications that can be associated with phenotypes that partially overlap with CFC.25–26 If all of the above are negative, the geneticist can consider whole exome or genome sequencing for diagnosis.

**CLINICAL DESCRIPTION WITH DIFFERENTIAL DIAGNOSIS**

Clinical features of CFC begin in the prenatal period with ultrasound findings of increased nuchal lucency and, sometimes, cystic hygroma.27,28 Polyhydramnios is very common (77%) and premature

---

**TABLE 1 Continued**

<table>
<thead>
<tr>
<th>Clinical Specialty</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing management:</td>
<td>• Appropriate hygiene.</td>
</tr>
<tr>
<td></td>
<td>• Restorative care.</td>
</tr>
<tr>
<td></td>
<td>• Orthodontic treatment as needed.</td>
</tr>
</tbody>
</table>

CBC, complete blood cell; FTT, failure to thrive.
Birth is present in up to a half of pregnancies. Craniofacial characteristics, coupled with features such as cardiac disease, feeding difficulty, and developmental delay, are often the first diagnostic clues after birth suggesting the diagnosis of CFC. In 2002, a CFC index was developed based on 82 clinical traits to assist with diagnosis. However, at present, there are no pathognomonic or obligatory features uniquely associated with CFC that can aid in making a definitive clinical diagnosis.

The head and face are characterized by macrocephaly/relative macrocephaly, tall forehead with bitemporal narrowing, increased facial width and depth, coarse facial features, and small chin. Sparse, curly, and friable hair, with sparse or absent eyebrows with hypertelorism (ulerythema ophryogenes) are very common in CFC and occur with greater frequency than in other RASopathies. Ocular features include ptosis, hypertelorism, downslanting palpebral folds, and high arched forehead with bitemporal narrowing. The nose is often short with a broad nasal base, bulbous tip, and anteverted nares. The mouth is wide with a deeply grooved philtrum and Cupid’s bow contour of the upper vermilion border. The palate is narrow and high arched with a short, broad or bifid uvula. Ears are posteriorly angulated and low set. With age, the face may become coarser and facial characteristics less pronounced (Fig 1 A and B).

Many of the clinical features of CFC overlap with those of NS and CS (Table 2). Other conditions to be considered in the differential diagnosis of CFC include NS with multiple lentigines, Baraitser-Winter syndrome, and NS with loose anagen hair. Because of differences in the medical management, long-term prognosis, and genetic risks, obtaining the correct diagnosis is very important among these syndromes with overlapping features.

**CARDIAC ISSUES**

Nearly 75% of individuals with CFC have cardiovascular involvement of various kinds (Table 3). As soon as clinical findings of CFC are recognized or a diagnosis of CFC is confirmed, a consultation with a pediatric cardiologist and echocardiography should be obtained. The most common cardiac problem is pulmonary valvar stenosis (PVS), present in ~45% of individuals, sometimes with a dysplastic pulmonary valve. PVS may occur alone or concomitantly (in nearly 20%) with other cardiac defects, such as atrial septal defect or HCM. The cardiologist may consider cardiac catheterization and balloon angioplasty if the PVS is severe, although it is not always successful. Surgery may also be recommended by the cardiologist in preference to balloon angioplasty, especially if there are multiple cardiac defects. The surgery might include pulmonary valvotomy and correction of other defects as necessary.

HCM, present in nearly 40% of individuals with CFC, can occur in infancy and have a wide variation in severity, sometimes rapidly progressive, even resulting in death or cardiac transplantation. Others have only mild cardiac thickening that is not progressive and may improve with time. One adult with HCM detected shortly before his death at age 21 years also had pulmonary hypertension and pulmonary vascular changes (Grade 3 Heath/Edwards) on autopsy. In general, children and adults with CFC and mild HCM may require only periodic reevaluation with their cardiologist. Those with more significant HCM could require treatment with β-blocker medications or surgical procedures including myomectomy to decrease outflow obstruction.

Other forms of heart disease (Table 3) seen in CFC are atrial septal defect (18% to 28%), ventricular septal defect (11% to 22%), and other rarer defects such as mitral valve dysplasia, coarctation of the aorta, and subaortic stenosis. Each of these conditions and those in Table 3 are managed by a cardiologist who determines reevaluation frequency and plans interventions as necessary including cardiac catheterization, medication management, device closure for septal defects, and surgical procedures.

Arrhythmias are uncommon in CFC, when compared with CS where they occur more frequently. Types of arrhythmias previously documented include the following: supraventricular tachycardia, atrioventricular block, and Wolff–Parkinson–White. Consultation with a cardiologist is recommended for management of arrhythmias.

Little is known about the natural history of heart disease in CFC and whether heart abnormalities such as myocardial thickening/dysfunction (HCM) can develop at older ages. All patients with CFC, even those who have had previous normal echocardiograms or underwent surgical repair of congenital heart defects as young children, should have periodic cardiac reevaluation by a cardiologist.

**DERMATOLOGIC MANIFESTATIONS**

Dermatologic manifestations are cardinal features of CFC, important for clinical diagnosis and differentiating CFC from other RASopathies. Although the severity and type of cutaneous involvement varies (Table 3), virtually all CFC individuals develop some form of cutaneous involvement and for this reason, dermatologic consultation and follow-up are recommended. Among the manifestations are wavy or curly scalp hair, with sparse hair at the temples,
poor hair growth, and sparse arm and leg hair. Ulerythema ophryogenes, characterized by brow erythema with loss of follicles, causes sparse or absent eyebrows with only 10% of individuals having normal eyebrows. Numerous acquired melanocytic nevi are striking features of CFC, with this finding less common in other RASopathies. It is not uncommon for individuals to develop over 100 nevi as they age, with the nevi not restricted to light-exposed areas. To date, there are no reports of malignant transformation of pigmented lesions in CFC.

Keratosis pilaris (follicular hyperkeratosis of the extremities and/or face) is also seen in the majority of cases. Individuals with CFC have a high rate of heat intolerance, may sweat excessively, and develop axillary body odor due to hyperkeratosis. Other dermatologic findings in CFC include dry skin, eczema, dystrophic nails with rapid nail growth, generalized hyperpigmentation, ear lobe creases, acanthosis nigricans, hyperplastic nipples, and creases on the fingertips. Nasal and perianal papillomata, typically seen in CS, are uncommon in CFC. Infantile hemangiomas, seen in 25% of CFC individuals, higher than other RASopathies, have a similar natural history to those in the general population. Some skin manifestations evolve over time and are usually seen in adolescence and adulthood. Palmo-plantar calluses...
can develop especially in pressure areas, and peripheral lymphedema is occasionally present, most often affecting the lower limbs.32 Those with lymphedema can be referred to vascular/lymphedema clinics for management. Early treatment of skin infections is recommended in those with lymphedema.

**NEUROLOGIC FINDINGS**

Neurologic abnormalities are universally present in CFC and range from mild to severe.40 Hypotonia, motor delay, speech delay, and learning disability can be considered main features (Table 3). Neurologic examination typically will demonstrate macrocephaly, hypotonia, ocular abnormalities, corticospinal tract findings, touch sensitivity, and tactile defensiveness.29,41,42 Peripheral neuropathy has been rarely documented in CFC, but may be underdiagnosed.43,44 Brain MRI studies reveal structural malformations in 9% to 85% of patients with CFC.42 Abnormalities include ventriculomegaly, hydrocephalus, cortical atrophy, prominent Virchow-Robin spaces, and abnormal myelination.40,42 Other structural anomalies such as type I Chiari malformation, arachnoid cyst, gray matter heterotopia, corpus callosum abnormalities, cerebellar calcification, and periventricular leukoencephalopathy have been reported.40–42 It has been suggested that central nervous system malformations are underreported in CFC because only 38% to 50% of children have had brain MRI or computed tomography scans.42,44 The fact that many children with CFC do have structural brain malformations suggests the need for brain imaging in patients with CFC, as finding morphologic brain changes could lead to better understanding of the individual's neurologic findings or underlying diagnosis. For example, individuals with NS have relatively few central nervous system malformations, and a brain MRI with some of the above structural abnormalities may suggest a diagnosis of CFC rather than NS.

Unlike other RASopathies, seizures of various types may affect ~40% to 50% of children with CFC.29,40 Seizure types may include complex partial, generalized tonic-clonic, absence seizures, and/or infantile spasms.40 Infantile spasms, which are relatively rare in the general population, are a common seizure type in CFC.40,45,46 When there is clinical suspicion for infantile spasms or other seizures, an urgent sleep EEG should be obtained along with consultation with a neurologist. Prompt diagnosis and subsequent treatment is critical in
infantile spasms to avoid permanent neurodevelopmental sequelae. Seizures in CFC are often refractory to medications, requiring several anticonvulsants. Polytherapy may lead to an increased risk of medication-related side effects that could impact individuals with CFC who already have learning disability and developmental delay. Long-term neurologic reevaluation can be organized by the neurology consultant on the basis of need for ongoing seizure management.

COGNITIVE AND BEHAVIORAL
Relatively few studies have reported on neuropsychological sequelae of CFC. Skills in intellectual, motor, social, communicative, and behavioral functioning vary widely. Intellectual disability is present in 90% to 100% of individuals with CFC, yet IQs in the low average to average range have been reported among a few individuals with BRAF mutations. Gross motor skills tend to be more delayed in the early years (ie, birth to age 6 years) than fine motor skills, perhaps due to the high incidence of hypotonia. Mean age of walking without assistance is reported to be around 3 years, although ~18% of individuals with CFC are unable to achieve independent walking. Language abilities range from limited nonverbal communication to capacity to speak in full sentences. On average, children with CFC speak their first word around 2 years of age, although 9% to 31% remain nonverbal. Progress in basic language development can continue well into adolescence. Receptive language ability is typically stronger than expressive language. Many families report using simple sign language or assistive technologies to facilitate communication.

In academic settings, virtually all children with CFC receive special education services such as speech/language therapy, occupational therapy, physical therapy, and/or assistance of a paraprofessional. School performance can vary from profound disability (with minimal/static developmental progress) to mild disability (with achievement of basic reading, writing, and math skills). Behaviorally, many families report concerns related to irritability, short attention span, stubbornness, and obsessive or aggressive behaviors. Sensory processing problems (eg, tactile defensiveness) and a heightened risk for autism spectrum disorder traits have also been reported. Sleep problems are common, including poor sleeping patterns, night sweating, sleep apnea, and night terrors.

Although research to evaluate the effectiveness of behavioral treatments in CFC is currently lacking, studies of individuals manifesting similar characteristics suggest likely avenues for successful intervention. Therapies focused on expanding functional communication (eg, interventions incorporating sign language, discrete-trial training or naturalistic [“milieu”] teaching) have demonstrated efficacy in individuals with intellectual disabilities and those with autism spectrum disorders. Parent-training interventions to manage behavior or promote specific skills have also proven successful. Approaches such as personalized schedules and functional behavior assessments have demonstrated effectiveness in children with similar neurologic and behavioral impairments. Finally, treatments targeting difficulties with sensory processing have the potential to improve functioning. Given the wide variability in clinical characteristics in CFC, tailoring intervention to each child’s unique developmental trajectory is essential, as is coordinated implementation of services across the home, medical, and educational settings.

GASTROINTESTINAL AND GROWTH ISSUES
Failure to thrive and poor growth in infancy are almost universal in CFC. These are usually accompanied by severe feeding problems including gastroesophageal reflux, suck/swallow dysfunction, and oral aversion. The swallowing difficulties are reflected early by prenatal polyhydramnios that, after birth, is followed by difficulty in maintaining adequate oral caloric intake. Prolonged supplemental feedings via nasogastric tube feedings or gastrostomy tube placement are common (40% to 50%) in CFC. Many still require assisted feeding in late childhood and adolescence. Respiratory complications such as choking, aspiration pneumonia, and chronic raspy breathing are also related to the swallowing/oropharyngeal difficulties. Oral aversion and sensory integration difficulties with solid foods can persist into adulthood.

Severe feeding difficulties, gastroesophageal reflux, and failure to thrive in an infant with facial features similar to NS along with cardiac disease should suggest the possible diagnosis of CFC. An early evaluation by a gastroenterology specialist is recommended in infancy or at the time of diagnosis to allow guidance in testing and decisions regarding necessity of supplemental feedings or surgeries such as fundoplication. Feeding therapy is suggested at the first sign of oral aversion. Treatment of gastroesophageal reflux with proton pump inhibitors may be of some value.

Constipation related to intestinal dysmotility is often seen in children with CFC and can remain a lifelong problem. Gastroenterologists can differentiate the constipation caused by intestinal dysmotility from other less common conditions such as intestinal malrotation, functional megacolon, anal stenosis, or rarely intestinal atresia. Constipation can continue into adulthood and follow-up by a gastroenterologist may be helpful in planning a satisfactory bowel regimen.
ENDOCRINE ISSUES

Short stature is a common feature in all RASopathies. This is not surprising since the Ras/MAPK pathway plays a major role in mediating the intra-cellular signaling of Insulin-like Growth Factor (IGF-1), which mediates postnatal growth effects of growth hormone (GH). In addition, MAPK activation is important in regulating the proliferation of pituitary somatotrophs that synthesize and release GH. Therefore, dysregulation of the Ras/MAPK signaling pathway may contribute, along with other intrinsic and extrinsic factors, to growth failure and short stature.

It is estimated that two-thirds of children with CFC have short stature. The exact cause of short stature is not well established; some individuals may have GH deficiency, whereas some may have GH resistance. In addition, inadequate nutrition, due to the high prevalence of feeding problems in CFC, might contribute to failure to thrive, poor growth, and possibly IGF-1 deficiency. Although GH therapy is approved by the Food and Drug Administration for short stature in NS, the use of GH in CFC has not been studied. For children with NS, GH use may result in short-term improvement in growth velocity and a modest gain in final adult height. Studies on the benefits of GH therapy in CFC are needed. Currently, the only approved use of GH in CFC is for those with documented GH deficiency.

Monitoring linear growth throughout infancy and childhood is essential to identify growth concerns early. Individuals with height consistently below the third percentile or with poor growth velocity should be evaluated for growth failure. If weight gain is suboptimal and there are feeding difficulties and poor caloric intake, gastrointestinal evaluation is warranted.

Recent reports have suggested a higher incidence of autoimmunity in those with a RASopathy. Because autoimmune thyroiditis is common in the general population, measurements of thyroid function are recommended at diagnosis. Only a few instances of hypothyroidism have been documented in CFC, so follow-up thyroid testing can be decided by an endocrinologist. Autoimmunity in CFC is an area that could benefit from future research.

Puberty may be delayed in individuals with CFC. Health care providers should be mindful of monitoring Tanner staging annually beginning at 10 years of age. Endocrine evaluation is appropriate if onset of puberty is delayed beyond age 12 to 13 years.

MUSCULOSKELETAL CONDITIONS

Musculoskeletal findings are seen in all RASopathies but are particularly prominent in CFC. Global hypotonia is evident on clinical examination especially in the newborn period and is manifested by delayed motor skills, muscle weakness, and decreased muscle bulk. As children grow older, muscle weakness appears to gradually improve, although individuals still may have gross motor delays.

Skeletal muscle strength does not appear to completely normalize and muscle bulk usually remains underdeveloped, and may actually decrease in older individuals. The origin of hypotonia in CFC is unclear, as it may arise from central nervous system dysfunction, muscle pathology, or a combination of the two. Skeletal muscle biopsies of CFC demonstrate relatively normal architecture, but abnormal muscle fiber size and variability, with a predominance of type 2 muscle fibers. In addition, some preliminary observations have described individuals with CFC with oxidative phosphorylation dysfunction and muscular coenzyme Q10 deficiency. Orthopedic conditions in CFC (Table 3) occur with high frequency and cause significant disability, so referral to an orthopedist is recommended at diagnosis. Individuals may have scoliosis and/or kyphosis, pectus excavatum and/or carinatum, joint hyperextensibility, joint contractures, pes planus, and dysfunctional gait. The need for a walker is not uncommon.

Scoliosis occurs in ~33% of individuals with CFC and mimics idiopathic or neurogenic scoliosis, without evidence of overt vertebral malformations. Type I Chiari malformations have been found on MRI studies, and such malformations have been linked to the development of scoliosis. Pes planus or planovalgus is seen in two-thirds of individuals with CFC and tends to be more severe than in the general population, with significant forefoot valgus. Treatment is generally nonsurgical; however, those with severe deformity and/or significant functional impairment may require surgical correction.

Osteopenia has been anecdotally reported, and there is biochemical evidence of increased bone resorption in several RASopathies, including CFC; however, the clinical consequence of increased bone resorption in this population is not yet known.

OPHTHALMOLoGIC FEATURES

Ocular manifestations in CFC occur in the majority of individuals. Commonly reported findings include strabismus, refractive errors, nystagmus, ptosis, and optic nerve hypoplasia. Craniofacial abnormalities related to the eyes include hypertelorism, epicanthal folds, and hypoplastic supraorbital ridges. A recent study of a large cohort of mutation-positive individuals with CFC identified the above findings, as well as problems with depth perception and reduced visual acuity. A number of children undergo strabismus correction in early infancy or early childhood, with...
Therefore, audiologic assessment and otolaryngology consultation is recommended on diagnosis. Laryngotracheal abnormalities such as laryngotracheomalacia and laryngeal clefts are also seen in CFC. Some young infants have required tracheostomy because of marked laryngomalacia and require long-term care by an otolaryngologist (Table 1).

**RENAL/GNITOURINARY FINDINGS**

Renal and genitourinary abnormalities occur in ~17% to 33% of individuals with CFC. Renal cysts, medullary nephrocalcinosis, nephrolithiasis, hydronephrosis, and hydroureteronephrosis have all been reported. Cryptorchidism has been found in two-thirds of male patients, similar to the incidence in NS.

**HEMATOLOGY/ONCOLOGY CONDITIONS**

Unlike NS, easy bruising and bleeding problems have not been reported as frequently in CFC. There is 1 report of transient thrombocytopenia in a newborn and 1 with a history of frequent epistaxis. One individual has been reported with von Willebrand disease. If easy bruising and bleeding problems are present on diagnosis or appear with time, screening for platelet abnormality and von Willebrand disease is recommended.

Although the mutations causing CFC are in a well-known oncogenic pathway, it is unclear if individuals with CFC are at an increased risk for malignancies. In ~200 individuals with CFC reported in the literature, 3 have been found to have acute lymphoblastic leukemia, one with non-Hodgkin lymphoma, and one with large B-cell lymphoma. One individual with CFC (BRAF mutation) had a hepatoblastoma, possibly the result of postcardiac transplant immunosuppression. Additional studies are needed to accurately assess the risk of malignancy in CFC.

**ORAL/DENTAL ISSUES**

Individuals with CFC have a characteristic dental phenotype including malocclusion with open bite, posterior crossbite, high labial frenal attachment, and high-arched palate. Oral habits may include tongue thrusting, bruxism, and open mouth posture. Dental development typically follows the timing present in the general population with normal eruption patterns, although ~10% of individuals may be delayed. Dental crowding may be seen, but not at a higher frequency than the general population. It is rare to observe hypodontia, gingival hyperplasia, or supernumerary teeth. Dental caries are typical though the enamel is clinically normal. Overall, there is not a unique dental pathology requiring specific treatment, but routine dental examinations, appropriate hygiene, restorative care, and orthodontic care if needed are recommended. Due to neurocognitive delay and oral aversion, some may exhibit anxiety during dental examinations. Thus, these individuals should be seen early and often to acustom them to dental treatment.

**SUMMARY**

This report provides health professionals with current information with regard to the diagnosis and best practices of care for individuals with CFC (Table 1). It is important to understand that CFC is a variable and genetically heterogeneous disorder caused by mutations of genes in the Ras/MAPK pathway. Like other RASopathies, recognizable facial features, congenital heart disease, and short stature characterize CFC. In addition, CFC also has cutaneous and neurologic involvement. Because of the many aspects of CFC described herein, multidisciplinary care is essential. The prognosis of many aspects of CFC is still unknown, and full understanding of...
care expectations during childhood and adulthood is yet to be established.

ACKNOWLEDGMENTS
A consensus conference was organized by CFC International to bring together health care professionals and researchers with particular expertise in the care of individuals with CFC. Funding for the consensus conference was provided by CFC International through donations to their organization for educational efforts. None of the participants received honorariums for the conference. We thank Dr G. Zampino for helpful comments about the gastrointestinal section.

REFERENCES

Dr M.E. Pierpont was Chair of the CFC Consensus Conference, designed the agenda of the CFC Consensus Conference, invited the participants of the CFC Consensus Conference, participated in the Conference and in writing the manuscript, coassembled the manuscript, edited the manuscript, reviewed and revised the manuscript, and approved the management recommendations; Ms Magoulas assisted in conceptualizing the CFC Consensus Conference, participated in the Conference and in writing the manuscript, coassembled the manuscript, designed the figures, reviewed and revised the manuscript, and approved the management recommendations; Drs Adi, Kavamura, Neri, Noonan, E.I. Pierpont, Reinker, Roberts, Shankar, Sullivan, and Wolford, participated in the CFC Consensus Conference and in writing the manuscript, reviewed and revised the manuscript, and approved the management recommendations; Ms Conger and Ms Santa Cruz were responsible for conceptualizing and planning the CFC Consensus Conference, participated in the CFC Consensus Conference, reviewed and revised the manuscript, and approved the management recommendations; Dr Rauen was Co-Chair of the CFC Consensus Conference, codesigned the agenda of the CFC Consensus Conference, participated in the CFC Consensus Conference and in writing the manuscript, coassembled the manuscript, edited the manuscript, reviewed and revised the manuscript, and approved the management recommendations; and all authors approved the final manuscript as submitted.

www.pediatrics.org/cgi/doi/10.1542/peds.2013-3189
doi:10.1542/peds.2013-3189

Accepted for publication Apr 23, 2014

Address correspondence to Mary Ella Pierpont, MD, PhD, Department of Pediatrics, University of Minnesota, 2450 Riverside Ave, East Building Mail Code 8952G, Minneapolis, MN 55454. E-mail: pierp001@umn.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: CFC Consensus Conference (November 5–6, 2012) supported in part by CFC International, Vestal, New York. Dr Rauen is funded in part by National Institutes of Health RO1-AR062185. Funded by the National Institutes of Health (NIH).

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management Guidelines

Pediatrics 2014;134;e1149
DOI: 10.1542/peds.2013-3189 originally published online September 1, 2014;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/134/4/e1149

References
This article cites 74 articles, 7 of which you can access for free at:
http://pediatrics.aappublications.org/content/134/4/e1149.full#ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints
Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management Guidelines

Pediatrics 2014;134;e1149
DOI: 10.1542/peds.2013-3189 originally published online September 1, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/134/4/e1149